

16 October 2026

ASX ANNOUNCEMENT

APPOINTMENT OF CHIEF FINANCIAL OFFICER

Paragon Care Limited (ASX: PGC) ("ParagonCare" or the "Company") announces the appointment of David Collins as Chief Financial Officer, effective immediately. David will continue to serve as an Executive Director of ParagonCare while assuming the responsibilities of Chief Financial Officer. He succeeds Brendon Pentland, who has stepped down from the role, effective today.

David's depth of knowledge of the business and the market is more aligned with our current business requirements which have expanded in complexity to cover 11 countries across 4 distinct sales channels.

The Board thanks Brendon for his contribution to ParagonCare and acknowledges the role he has played in supporting the Company's strategic initiatives and financial management. The Board wishes Brendon well in his future endeavours.

In accordance with ASX Listing Rule 3.16.4, the material terms of David Collins' employment arrangements, which remain unchanged, are summarised below:

- Fixed remuneration: \$800,000 per annum inclusive of superannuation
- Short-term incentive opportunity: up to 50% of fixed remuneration
- Long-term incentive participation: subject to shareholder approval and Board discretion
- Notice period: 12 months

ENDS

For further information please contact:

Carmen Riley
Chief Executive Officer & Managing Director
carmen.riley@paragoncare.com.au

This announcement is authorised for release to the market by the Board of Paragon Care Limited.

About Paragon Care Limited

Paragon Care Limited (ASX:PGC) is an Australian based listed company in the healthcare sector. It is a leading provider of medical equipment, devices, consumables, pharmaceuticals, complementary medicines, nutritional supplies and manufacturer of Blood Bank diagnostic reagents to the healthcare markets in Australia, New Zealand and Asia.